The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of Genoptix, Inc. by Novartis AG
24 Janvier 2011 - 8:29PM
Business Wire
Robbins Umeda LLP has commenced an investigation into possible
breaches of fiduciary duty and other violations of state law by
members of the board of directors of Genoptix, Inc. (NASDAQ:GXDX)
in connection with their efforts to sell the company to Novartis AG
(NYSE:NVS). If the transaction is completed, Genoptix shareholders
will receive $25.00 in cash for each share of Genoptix common stock
they hold. The transaction is expected to close in the first half
of 2011.
Robbins Umeda LLP's investigation concerns whether the Genoptix
board undertook a fair process to obtain fair consideration for its
shareholders. Specifically, the investigation concerns whether
members of the Genoptix board breached their fiduciary duties to
its shareholders by failing to adequately shop the company before
entering into the transaction with Novartis.
If you are a shareholder of Genoptix, plan to continue to hold
your shares, and would like more information about your rights as a
shareholder, please contact attorney Gregory E. Del Gaizo at
800-350-6003 or by e-mail at info@robbinsumeda.com.
Robbins Umeda LLP represents individual and institutional
shareholders in derivative, direct, and class action lawsuits. The
law firm's skilled litigation teams include former federal
prosecutors, former defense counsel from top multinational
corporate law firms, and career shareholder rights lawyers. Robbins
Umeda LLP has helped its clients realize more than $1 billion of
value for themselves and the companies in which they have invested.
For more information, please go to http://www.robbinsumeda.com.
Attorney Advertising. Past results do not guarantee a similar
outcome. We invite you to contact us today to discuss your
case.
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about Genoptix, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Robbins Umeda LLP